|
Horse antithymocyte globulin as salvage therapy after rabbit antithymocyte globulin for severe aplastic anemia
|
Jan 2014
|
Am J Hematol
|
aplastic anemia
|
|
Impact of Achievement of Complete Cytogenetic Response on Outcome in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents
|
Jan 2017
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R
|
Sep 2017
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Effectiveness of eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) with or without aplastic anemia in the International PNH Registry
|
Jan 2019
|
Am J Hematol
|
aplastic anemia, paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Toward complement inhibition 2.0: Next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria
|
Jan 2018
|
Am J Hematol
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management
|
Jan 2014
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Effect of race on outcomes after allogeneic hematopoietic cell transplantation for severe aplastic anemia.
|
Oct 2013
|
Am J Hematol
|
aplastic anemia
|
|
IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution.
|
Oct 2013
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Real-Life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile
|
Jan 2014
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
|
Evaluation of revised IPSS cytogenetic risk stratification and prognostic impact of monosomal karyotype in 783 patients with primary myelodysplastic syndromes.
|
May 2013
|
Am J Hematol
|
myelodysplastic syndromes (MDS)
|
